Proteome Sciences PLC (GB:PRM)
LSE:PRM
Want to see GB:PRM full AI Analyst Report?
PRM Stock Chart & Stats
2.85 p
-0.10 p(-2.84%)
At close: 4:00 PM EST
2.85 p
-0.10 p(-2.84%)
Day’s Range― - ―
52-Week Range1.20 p - 4.40 p
Previous CloseN/A
Volume41.42K
Average Volume (3M)476.64K
Market Cap
£5.30M
Enterprise Value19.61M
Total Cash (Recent Filing)£781.00K
Total Debt (Recent Filing)£15.77M
Price to Earnings (P/E)―
Beta0.37
Next Earnings
Jul 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding350,724,900
10 Day Avg. Volume209,671
30 Day Avg. Volume476,642
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)-0.77
Price to Sales (P/S)1.96
P/FCF Ratio-51.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Service-based Contract Research ModelA service-based model selling proteomics and mass-spec contract research creates durable revenue channels from pharma, biotech and academic customers. Long-term projects and repeat engagements provide predictable demand and client stickiness, supporting revenue stability over months.
Specialized Proteomics And Mass-spectrometry ExpertiseDeep technical specialization in proteomics and mass spectrometry is a structural competitive advantage. High technical barriers and specialized lab capabilities foster long-term client relationships, limit easy substitution, and support higher switching costs for pharma/biotech partners.
Near‑breakeven Operating Cash Flow TrendImprovement to near‑breakeven operating cash flow reflects better cash conversion and expense control versus prior years. Sustained cash flow stabilization reduces short-term refinancing needs and, if maintained, supports funding ongoing operations and selective investment without immediate equity dilution.
Bears Say
Declining Revenue TrendA meaningful revenue decline reduces economies of scale and weakens the firm's ability to spread fixed laboratory and personnel costs. If the downtrend persists, it will pressure margins, limit reinvestment in capabilities, and make consistent profitability recovery harder over a 2–6 month horizon.
Negative Gross Profit And Sustained Operating LossesNegative gross profit signals structural issues in pricing or direct cost control for lab services. Persistent operating losses of multi‑million pounds indicate the core business is not covering direct and overhead costs, impairing ability to self-fund growth or weather further revenue setbacks.
Weak Balance Sheet And Rising LeverageHigh debt with deeply negative equity creates refinancing and solvency risk. With assets well below liabilities, the company has limited financial flexibility to invest, pursue partnerships or absorb shocks; this structural weakness increases probability of dilution or covenant pressure over months.
Proteome Sciences News
PRM FAQ
What was Proteome Sciences PLC’s price range in the past 12 months?
Proteome Sciences PLC lowest share price was 1.20 p and its highest was 4.40 p in the past 12 months.
What is Proteome Sciences PLC’s market cap?
Proteome Sciences PLC’s market cap is £5.30M.
When is Proteome Sciences PLC’s upcoming earnings report date?
Proteome Sciences PLC’s upcoming earnings report date is Jul 23, 2026 which is in 32 days.
How were Proteome Sciences PLC’s earnings last quarter?
Proteome Sciences PLC released its earnings results on Apr 15, 2026. The company reported -0.003 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.003 p.
Is Proteome Sciences PLC overvalued?
According to Wall Street analysts Proteome Sciences PLC’s price is currently Overvalued.
Does Proteome Sciences PLC pay dividends?
Proteome Sciences PLC does not currently pay dividends.
What is Proteome Sciences PLC’s EPS estimate?
Proteome Sciences PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Proteome Sciences PLC have?
Proteome Sciences PLC has 350,724,900 shares outstanding.
What happened to Proteome Sciences PLC’s price movement after its last earnings report?
Proteome Sciences PLC reported an EPS of -0.003 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.762%.
Which hedge fund is a major shareholder of Proteome Sciences PLC?
Currently, no hedge funds are holding shares in GB:PRM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Proteome Sciences PLC
Proteome Sciences plc, established in 1993 and based in Cobham, United Kingdom, specializes in delivering contract research services. The company's core expertise lies in the identification, validation, and practical application of protein biomarkers for clients across the United States, the United Kingdom, and the European Union. Its extensive portfolio includes a range of sophisticated proteomic solutions: SysQuant offers comprehensive insights into protein activity within regulatory and signaling pathways. For analyzing cells and tissues without the need for phosphopeptide enrichment, they provide TMT MS2. TMT MS3 is a critical method for biomarker discovery in complex samples, such as plasma, where precise quantification is paramount. The TMT Calibrator enables simultaneous analysis of diseased or treated tissue alongside peripheral fluids. Rapid validation of biomarker candidates is facilitated by TMT SRM, a targeted assay format. Additionally, the company performs SRM assays, a targeted mass spectrometry technique for routine biomarker measurement. Complementing these laboratory services, Proteome Sciences also offers a suite of bioinformatics tools. These include: Proteome Discoverer, utilized for peptide sequencing and TMT quantification. SQuaT, CalDIT, and DIANA, which normalize quantitative data and provide functional annotation for peptides and proteins. FeaST, a visualization tool for assessing data quality, building class identifier models, and generating biomarker candidate lists. FAT, designed to identify variations in biological processes and cellular components. The company's primary clientele comprises pharmaceutical and biotechnology firms, as well as academic research institutions.
Technical Analysis
Options Prices
Currently, No data available
---